GEE DAVID NICHOLAS sold $25K of CLBT

GEE DAVID NICHOLAS (Chief Marketing Officer) sold 2,198 shares of Cellebrite DI Ltd. (CLBT) at $11.24 on 2026-08-21.

Original reporting
SEC EDGAR · GEE DAVID NICHOLAS
Published Aug 24, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLBT
Neutral
high confidence
Mentioned
$CLBT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The sale represents a routine liquidity event; no new strategic information.

02

Market read

Minor insider sell; limited impact on stock price or sector.

03

What to watch

Potential upcoming product launch or partnership not disclosed in filing.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-24

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$CLBTNeutralHigh confidence
Context

Chief Marketing Officer sold 2,198 shares for $24,709 via open-market transaction on 2026-08-21.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical 10b5‑1‑style sell.

Market effects

None; insider sale does not affect broader sector.

None; company is US‑listed with limited regional relevance.

None

Counterpoint

If the insider had material non‑public information, the sell could signal downside risk.

Key entities

  • Cellebrite DI Ltd.

    Provider of digital intelligence solutions, ticker CLBT.

  • GEE DAVID NICHOLAS

    Chief Marketing Officer of Cellebrite.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTHighAI 8/10

Cellebrite DI Ltd. (CLBT): Financial results for Q3 2026

Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and

$CLBTHigh

Cellebrite Reports Third-Quarter 2026 Results

Cellebrite reported Q3 2026 results with ARR up 20% to $528.5M, revenue up 18% to $149M, and adjusted EBITDA of $53.6M. CEO Shiv Ramji highlighted strong international and U.S. Federal performance, and raised 2026 adjusted EBITDA outlook to $163M-$166M. The company also announced plans to redomicile in the U.S. and progress with its Genesis AI solution.

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.